ARQT
ARQT
Positions held
Your positionsARQT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
2026-10-02 · Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 · Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
2026-09-21 · AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
2026-09-21 · Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
2026-09-17 · RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
2026-09-17 · Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
2026-09-17 · Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%
2026-09-04 · Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 · Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Price (daily)
Full chart · RSI · MACD · patterns